Corcept Therapeutics
CORT
286 hedge funds and large institutions have $2.9B invested in Corcept Therapeutics in 2024 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 103 increasing their positions, 115 reducing their positions, and 33 closing their positions.
31% more call options, than puts
Call options by funds: $47.4M | Put options by funds: $36.1M
23% more capital invested
Capital invested by funds: $2.36B → $2.9B (+$537M)
12% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 33
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% less funds holding
Funds holding: 287 → 286 (-1)
4.9% less ownership
Funds ownership: 90.62% → 85.73% (-4.9%)
10% less repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 115
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$14.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.64M |
| 3 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$4.96M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$4.87M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$4.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$18.3M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$13.7M |
| 3 |
Two Sigma Investments
New York
|
-$11.6M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$8.85M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$8.69M |
CORT Hedge Fund Activity: Q2 2024 in Review
286 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2024, worth a combined $2.9B — up 23% from $2.36B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CORT positions and 33 closed out — a net gain of 4 holders — while 103 added to existing stakes and 115 trimmed.
The largest buyer was Aberdeen Group, opening a new position worth an estimated $14.4M. The largest seller was Man Group, cutting an estimated $18.3M.
- 286 institutional investors held Corcept Therapeutics (CORT) as of Q2 2024, down from 287 in Q1 2024.
- Funds reported $2.9B of Corcept Therapeutics stock for Q2 2024, up 23% quarter-over-quarter.
- 37 funds opened new Corcept Therapeutics positions in Q2 2024 and 33 closed out, a net change of +4 holders.
- The largest Corcept Therapeutics buyer in Q2 2024 was Aberdeen Group, an estimated $14.4M added.
- The largest Corcept Therapeutics seller in Q2 2024 was Man Group, an estimated $18.3M sold.
Based on aggregated 13F filings for Q2 2024.